Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups
IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
2 Commerce Drive
Cranbury, NJ 08512